The best way to understand your PSA kinetics, especially its changes, is to be able to visualize them on a graph. This allows you to understand significant changes in our PSA earlier on than you might otherwise perceive them. Any man whether diagnosed with prostate cancer or not should be recording their PSA scores and [...]
It has been accepted that Zoledronic acid (ZA)(Zometa) reduces the onset risk of skeletal-related events (SRE) caused by bone metastasis in prostate cancer as well as improving their quality of life (QOL). ZA has become a standard supportive therapy for men with prostate cancer who have bone metastasis. However, there is an issue which I [...]
Malecare has recently launched a newsletter specifically about advanced, metastatic prostate cancer. This is the only Newsletter in publication that is dedicated exclusively to advanced prostate cancer. Everything in the newsletter is about advanced prostate cancer and every article is actionable by you. The Newsletter is about things that you can use today to improve [...]
As I have said before, the true unsung heroes of our fight against advanced prostate cancer are our caretakers. Our caretakers are our saints, they help educate us, they advocate for us, they shield us and they make us as complete as we can possibly be. They improve our lives and help us get through [...]
Some men with advanced prostate cancer have been given the antifungal treatment Ketoconazole (Keto) as a second line hormone treatment. Like Keto, this newer hormone treatment that is now available, Abiraterone acetate (AA) (Zytiga) works by inhibiting CYP17, the rate-limiting enzyme in androgen biosynthesis. The question being asked, if Keto has failed ,given its similar [...]
Since its FDA approval in 2011 FDA abiraterone (Zytiga) has supplanted docetaxel (chemotherapy), other than perhaps Provenge, as preferred first-line treatment for metastatic castrate-resistant prostate cancer. August 2012 saw the FDA approval of enzalutamide (Xtandi) for the treatment of castrate-resistant prostate cancer after chemotherapy. Researchers performed a retrospective chart review at a large medical oncology [...]
An uncommon, but very aggressive form of prostate cancer is known as Neuroendocrine prostate cancer (NEPC). It is generally accepted that Circulating Tumor Cell (CTC) counts as measured by CellSearch (a method to catch and count these cells in the blood) are prognostic for most men with metastatic prostate cancer (mPC), but are not well [...]
From: the 2014 ASCO GU Meeting Abstract No: 35 Researchers have found in a randomized controlled trial of men with metastatic castration-resistant prostate cancer (mCRPC) the use of the treatment denosumab was superior to the more commonly used zoledronic acid (ZA) for reducing skeletal-related events (SRE). SREs are defined as a pathological fracture, surgery or [...]
The novel radiopharmaceutical radium-223 (Xofigo) appears to have long term safety with minimal adverse events. In an updated report, given at ASCO GU, on the ALSYMPCA trial of radium-233 (Xofigo), the researchers have found that there is no major safety issues identified within ~1.5 years after the completion of treatment in a population of men [...]
Men with metastatic castration-resistant prostate cancer (mCRPC) in Québec, Canada now have access to Zytiga (abiraterone acetate) prior to having chemotherapy. Effective February 3, 2014, the province has added ZYTIGA to the public drug formulary for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT). [...]
